Celcuity Inc.
CELC | NASDAQ
$84.21
+$0.21 (+0.25%)
Sep 22, 2026, 1:11 PM ET · Market open
Company Profile
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer |
| Vicky Hahne | Chief Financial Officer |
| Brent Eilefson | General Counsel |
| Eldon C. Mayer | Chief Commercial Officer |
| Igor Gorbatchevsky | Chief Medical Officer |
| Jodi Sievers | Head of Investor Relations & Corporate Communications |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director |
| Sheri Smith | Acting Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 13, 2026 | 8-K | Current Report |
| Aug 11, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 16, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 16, 2026 | SC 13D/A | [Amend] Filing |
| Jul 16, 2026 | 4 | Filing |
Celcuity Inc.
| Country | United States |
| IPO Date | Sep 18, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Brian F. Sullivan |
Contact Details
2800 Campus Drive Minneapolis,
Minnesota 55441 United States
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Recent News
- 13 days ago / seekingalpha.comCelcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
- 21 days ago / globenewswire.comCelcuity To Participate in Upcoming Investor Conferences
- 27 days ago / globenewswire.comCelcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
- 29 days ago / defenseworld.netBrandywine Managers LLC Acquires New Stake in Celcuity, Inc. $CELC
- 1 month ago / seekingalpha.comCelcuity: REVTORPYK Is Now A Commercial Story
- 1 month ago / benzinga.comCelcuity Analysts Slash Their Forecasts After Q2 Loss
- 1 month ago / seekingalpha.comCelcuity Inc. (CELC) Q2 2026 Earnings Call Transcript
- 1 month ago / marketbeat.comCelcuity Q2 Earnings Call Highlights
- 1 month ago / globenewswire.comCelcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
- 1 month ago / defenseworld.netCalifornia State Teachers Retirement System Acquires 12,201 Shares of Celcuity, Inc. $CELC
Add to Watchlist
Select watchlists to add or remove CELC